You are here:

Valganciclovir (Valcyte)

Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION.

Valganciclovir has been approved for prevention of cytomegalovirus (CMV) disease in CMVnegative patients who have received a solid organ transplanted from a CMV-positive donor.

It can be given once daily compared with three times daily for existing treatment, thereby improving compliance and convenience.

Use of Valganciclovir should only be initiated by physicians in transplantation or infectious disease units.

Drug Details

Drug Name: Valganciclovir (Valcyte)
SMC Drug ID: 62/03
Manufacturer: Roche
Indication: prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplanted from a CMV-positive donor
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 8 September 2003

Back